Psychedelic Therapy in Portugal: Every Legal Route in 2026

If you are considering psychedelic-assisted treatment in Portugal — for yourself or for someone close to you — the picture in July 2026 has three working parts and two common misunderstandings. The working parts: publicly financed esketamine in hospital psychiatry, a small private ketamine-assisted psychotherapy market in Lisbon, and clinical trials. The misunderstandings: that Portugal's famous decriminalisation law makes psychedelic therapy legal (it does not), and that psilocybin or MDMA treatment can be booked somewhere (it cannot). This guide covers who qualifies for each real route, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.

At a glance

Esketamine (Spravato): hospital medicine under strict criteria

On 7 May 2025, INFARMED — Portugal's medicines authority — approved public financing of esketamine nasal spray for use in hospital settings in adults with treatment-resistant major depressive disorder (INFARMED decision notice). Portuguese media called it the first psychedelic-class medicine financed for severe depression (Público).

The criteria are stricter than in most European countries, and each element is load-bearing:

• At least three failed antidepressant treatments — different antidepressants, with combination or oral augmentation strategies, in the current moderate-to-severe depressive episode. Most of Europe requires two; Portugal requires three.
• Prior psychotherapy — you must have previously undergone psychotherapy.
• A documented position on electroconvulsive therapy (ECT) — resistance to ECT, a contraindication, lack of access, or a documented refusal.
• Esketamine is used in combination with an oral antidepressant (SSRI or SNRI), per the EU label (EMA product information).

How to start. The route runs through hospital psychiatry: your psychiatrist — or your GP via a psychiatric referral — refers you to a hospital psychiatric service, whose team applies the financing criteria before scheduling treatment. Administration and the post-dose observation period happen at the hospital. The practical currency is a written treatment history: every antidepressant and augmentation tried in the current episode (substance, dose, duration, outcome), your psychotherapy record, and — a step unique to Portugal's criteria — a documented discussion of ECT. Assembling that record before the first appointment does more work than anything you say in the room.

Cost and waiting. For patients who meet the criteria, treatment is financed within hospital care. Waiting depends on which hospitals in your region run an esketamine programme and how quickly your documentation comes together; the three-strategies-plus-psychotherapy record is often the slower part. For how Portugal compares with its neighbours, see our Europe-wide reimbursement map.

Ketamine-assisted psychotherapy: a small private market in Lisbon

Ketamine is a licensed medicine that Portuguese physicians may use off-label, which is legal and standard practice — and it supports a small but real private market, concentrated in Lisbon.

The Clinic of Change (theclinicofchange.com) opened in central Lisbon in June 2023 as the first Portuguese clinic offering a structured ketamine-assisted psychotherapy programme, initially built on the Awakn Life Sciences clinical protocol and, since June 2025, on its own methodology. Its published prices: an initial evaluation consultation at 120 euro, and a KAP programme at 3,900 euro for patients with insurance or 5,500 euro without, both payable in four instalments. The clinic also lists private Spravato treatment for treatment-resistant depression, psychiatry, clinical psychology and a pre-ketamine anesthesiology assessment. The insurance-linked price difference reflects what a policy can absorb of the surrounding consultations — ask the clinic for a written breakdown for your specific insurer before committing, because no Portuguese insurer routinely covers the ketamine-assisted component itself.

Liminal Minds (liminalminds.pt), in the Lisbon area (Miraflores, Algés), is registered with the Portuguese health regulator ERS and runs two modalities: antidepressant infusion therapy — a medically focused intravenous protocol for rapid symptom relief in resistant depression — and ketamine-assisted psychotherapy embedded in a psychotherapy course. Prices are not published; the clinic offers a free introductory phone call of 10–15 minutes with the clinical director.

How to start and what to check. You can self-refer to either clinic. Expect psychiatric and physical screening across more than one appointment before any treatment decision — that is a feature, not a delay. Ask for total programme cost in writing, what is included (preparation, sessions, integration, follow-up), and what happens if screening rules you out after the paid evaluation. To see who is listed, browse providers in Portugal.

Psilocybin: research only — one recruiting trial

Psilocybin remains a controlled substance in Portugal with no medical-access route. Two facts are worth separating. First, Portugal's decriminalisation framework (Law 30/2000) removes criminal penalties for possession for personal use — it does not license any therapy, clinic or retreat, and unregulated retreat offerings are not healthcare (Blossom: Portugal country report). Second, the clinical research is real and Lisbon-centred.

The honest status in July 2026:

• The one recruiting Portuguese psilocybin study is PsyPal, the EU-funded Phase 2 trial of psilocybin therapy for psychological distress in palliative care, with the Champalimaud Foundation in Lisbon as the Portuguese site — its arm focuses on people with late-stage parkinsonism (NCT06782724; Champalimaud Foundation).
• Portugal contributed to the completed Phase 2 COMP360 psilocybin trial in treatment-resistant depression that started in 2019 (Blossom: Portugal country report).
• In May 2025, a multidisciplinary working group — medical, pharmaceutical and psychological associations plus the National Ethics Council — presented national recommendations for the clinical use of psychedelic substances at the Champalimaud Foundation, a signal that Portuguese medicine is preparing for these treatments rather than offering them (Champalimaud Foundation).

If your situation fits the PsyPal profile, ask your treating physician about a referral to the Champalimaud study team. Outside a trial, anyone selling psilocybin therapy in Portugal today is operating without any legal medical basis.

MDMA: research participation only

MDMA remains a controlled substance in Portugal with no medical-access route, and as of July 2026 no Portuguese MDMA trial is recruiting — a ClinicalTrials.gov search for MDMA studies with Portuguese sites returns none. If MDMA-assisted therapy matters to you, the realistic options are watching the registries for new Portuguese studies or considering trial sites elsewhere in Europe — our trials guide explains how to search and what participation involves. Decriminalisation does not change this: anyone offering MDMA therapy commercially in Portugal today is operating outside the law that governs medicines and healthcare.

Clinical trials in Portugal

Blossom currently tracks 3 psychedelic clinical trials connected to Portugal, 1 of them active (Blossom: Portugal country report). The recruiting study is PsyPal at the Champalimaud Foundation; Portugal was also a site in the completed international Phase 3 ESCAPE-TRD esketamine trial and the completed Phase 2 COMP360 psilocybin trial. The ecosystem is small but institutionally serious, anchored by the Champalimaud Foundation's neuropsychiatry unit in Lisbon, with additional research capacity in Coimbra and Porto. Participation is free and legal, but screening is strict and enrolment is never guaranteed. See the trials guide for how phases, placebo and consent work, and search ClinicalTrials.gov for current Portuguese listings.

What to expect in treatment

Whichever route you take, the shape of care is similar and worth picturing in advance. It begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.

On a Spravato day you come to the hospital psychiatric service and self-administer the nasal spray under staff supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; a detached, dreamlike sensation and a temporary rise in blood pressure are expected effects that settle as the drug clears. You must not drive for the rest of the day, so arrange a ride home. Induction sessions are typically more frequent at first and then taper based on measured response, alongside a continuing oral antidepressant.

A ketamine session in a Lisbon KAP programme is usually built around a supervised administration — intravenous infusions run about 40–60 minutes — with the same vital-sign monitoring and a recovery period, wrapped in preparation and integration sessions with a therapist. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe, and psychotherapy or integration is what helps the effect last.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation, nausea, mild perceptual changes and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

• Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
• A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which trial screening checks carefully.
• Severe liver disease or other serious somatic illness — part of why The Clinic of Change includes an anesthesiology assessment before ketamine.
• Pregnancy or breastfeeding.
• Substance-use concerns, particularly patterns of compulsive use; clinics also screen for acute suicidality risk before admission.

A responsible provider screens for all of these before the first session. If a clinic is willing to treat you without that assessment, treat it as a warning sign.

Frequently asked questions

Is psychedelic therapy legal in Portugal because of decriminalisation?

No. Law 30/2000 removed criminal penalties for possession for personal use; it licensed nothing. Legal treatment in Portugal means hospital-financed esketamine, off-label ketamine at a licensed medical clinic, or a clinical trial — the same three categories as in the rest of Europe.

Why does The Clinic of Change charge less with insurance if insurers do not cover KAP?

Because parts of the surrounding care — psychiatric consultations, psychology sessions — can fall under a health policy even when the ketamine-assisted component does not. The published difference is 3,900 euro with insurance versus 5,500 euro without. Get a written breakdown for your specific insurer before starting.

Do I really need to have tried psychotherapy and considered ECT before hospital Spravato?

Under the May 2025 financing criteria, yes: prior psychotherapy and a documented position on ECT (resistance, contraindication, lack of access or refusal) sit alongside the three failed antidepressant strategies. Your psychiatrist documents these; raise them early so the record is complete.

Is psilocybin therapy available in Portugal right now?

Only inside a clinical trial. The one recruiting study is PsyPal at the Champalimaud Foundation, for psychological distress in palliative care. Retreats and informal offerings are not licensed healthcare, whatever their marketing says.

Can I get MDMA therapy in Portugal?

Not outside research, and no Portuguese MDMA trial is recruiting as of July 2026. Watch the registries or consider trial sites elsewhere in Europe.

How long will I wait for each route?

Hospital Spravato: mostly the time to get a psychiatric referral, assemble the three-strategies record and clear the hospital's own assessment — plan in months. Private KAP: the clinic's intake and multi-appointment screening, typically weeks. Trials: screening takes weeks, with no guarantee of enrolment, and can run in parallel.

Sources

1. INFARMED — Spravato (esketamine) public financing decision notice, 7 May 2025
2. Público: Infarmed aprova primeiro psicadélico para depressão grave a usar em meio hospitalar (12 May 2025)
3. Blossom: Portugal country report
4. Blossom: Medical access in Portugal
5. Psychedelic Alpha: Psychedelic Bulletin #197 — Portuguese health-related professions unite on psychedelics
6. Psychedelic Alpha: Worldwide psychedelic laws tracker
7. EMA: Spravato (esketamine) EPAR
8. ClinicalTrials.gov: NCT06782724 — PsyPal, psilocybin therapy for psychological distress in palliative patients (recruiting; Champalimaud Foundation site)
9. Champalimaud Foundation: EU funds psychedelic therapy research for treatment-resistant mental disorders in palliative care
10. Champalimaud Foundation: Recommendations for the clinical use of psychedelic substances presented (May 2025)
11. The Clinic of Change — Lisbon: programmes and published prices
12. Liminal Minds — Lisbon area: programmes

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and financing rules change; always verify current requirements with INFARMED, your hospital team, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number (in Portugal: 112, or the SNS 24 line 808 24 24 24) immediately.

This guide awaits review by a licensed medical professional.